» Articles » PMID: 11371364

Negative Selection at the Pre-BCR Checkpoint Elicited by Human Mu Heavy Chains with Unusual CDR3 Regions

Overview
Journal Immunity
Publisher Cell Press
Date 2001 May 24
PMID 11371364
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Approximately 9% of in-frame mu heavy chain transcripts found in normal human pro-B cells encode proteins that can be expressed on the cell surface in the absence of surrogate or conventional light chains. These unusual mu heavy chains demonstrate preferential use of certain VH genes (VH3-23), frequent expression of DH regions in underrepresented reading frames, and an increased number of positively charged amino acids within the CDR3 region. Transcripts for these proteins are not found in pre-B cells or in mature B cells. When expressed in Jurkat T cells with the Ig(alpha)/Ig(beta) signal transduction module, these aberrant mu heavy chains induce cell activation and apoptosis. These results suggest that some mu heavy chains elicit negative selection at the pro-B cell to pre-B cell transition.

Citing Articles

Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness.

Chen J, Qiu S, Li W, Wang K, Zhang Y, Yang H Cell Res. 2023; 33(5):341-354.

PMID: 36882513 PMC: 10156745. DOI: 10.1038/s41422-023-00789-0.


Dermatan Sulfate Is a Potential Regulator of IgH Interactions With Pre-BCR, GTF2I, and BiP ER Complex in Pre-B Lymphoblasts.

Lee J, Rho J, Roehrl M, Wang J Front Immunol. 2021; 12:680212.

PMID: 34113352 PMC: 8185350. DOI: 10.3389/fimmu.2021.680212.


Systemic translocation of Staphylococcus drives autoantibody production in HIV disease.

Luo Z, Li M, Wu Y, Meng Z, Martin L, Zhang L Microbiome. 2019; 7(1):25.

PMID: 30764863 PMC: 6376754. DOI: 10.1186/s40168-019-0646-1.


The Role of the Pre-B Cell Receptor in B Cell Development, Repertoire Selection, and Tolerance.

Winkler T, Martensson I Front Immunol. 2018; 9:2423.

PMID: 30498490 PMC: 6249383. DOI: 10.3389/fimmu.2018.02423.


Autoimmunity checkpoints as therapeutic targets in B cell malignancies.

Muschen M Nat Rev Cancer. 2018; 18(2):103-116.

PMID: 29302068 DOI: 10.1038/nrc.2017.111.